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Abstract
Inhibition of sulfonylurea receptor 1 (SUR1) by glyburide has been shown to decrease edema after subarachnoid
hemorrhage. We investigated if inhibiting SUR1 reduces cerebral edema due to metastases, the most common brain
tumor, and explored the putative association of SUR1 and the endothelial tight junction protein, zona occludens-1
(ZO-1). Nude rats were intracerebrally implanted with small cell lung carcinoma (SCLC) LX1 or A2058 melanoma cells
(n = 36). Rats were administered vehicle, glyburide (4.8 μg twice, orally), or dexamethasone (0.35 mg, intravenous).
Blood-tumor barrier (BTB) permeability (K trans) was evaluated before and after treatment using dynamic contrast-
enhanced magnetic resonance imaging. SUR1 and ZO-1 expression was evaluated using immunofluorescence and
Western blots. In bothmodels, SUR1 expressionwas significantly increased (P< .05) in tumors. In animals with SCLC,
control mean K trans (percent change ± standard error) was 101.8 ± 36.6%, and both glyburide (−21.4 ± 14.2%, P <
.01) and dexamethasone (−14.2 ± 13.1%, P < .01) decreased BTB permeability. In animals with melanoma, com-
pared to controls (117.1 ± 43.4%), glyburide lowered BTB permeability increase (3.2 ± 15.4%, P < .05), while
dexamethasone modestly lowered BTB permeability increase (63.1 ± 22.1%, P > .05). Both glyburide (P < .001)
and dexamethasone (P < .01) decreased ZO-1 gap formation. By decreasing ZO-1 gaps, glyburide was at least as
effective as dexamethasone at halting increased BTB permeability caused by SCLC and melanoma. Glyburide is a
safe, inexpensive, and efficacious alternative to dexamethasone for the treatment of cerebral metastasis–related
vasogenic edema.
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Introduction
Metastases are by far the most common type of brain tumor with an
annual incidence of more than 200,000 [1] in the United States,
approximately 10 times that of malignant primary brain tumors [2].
At least 10% [1] of adults with cancer develop symptomatic cerebral
metastases and incidence continues to rise [3,4] due to improved sys-
temic control and improved imaging detection. Cerebral metastases
cause significant edema and mass effect in 33% of patients [5] resulting
in decreased quality of life due to neurological deficits and headache.
By decreasing tumor vascular permeability [6–8], glucocorticoids
are the mainstay treatment of edema caused by cerebral metastases [9].
However, glucocorticoid use is associated with a multitude of dose-
and time-dependent adverse side effects such as immunosuppression
and endocrinopathies [10]. Newer vascular targeting agents such as
bevacizumab, a monoclonal antibody targeting vascular endothelial
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growth factor (VEGF), also rapidly decrease brain tumor permeability
[11,12] and tumor-associated edema in malignant gliomas [13,14] but
are cost prohibitive for many patients [15]. The need for a safe, inexpen-
sive, novel agent that effectively decreases blood-tumor barrier (BTB)
permeability and reduces vasogenic edema is of paramount importance.
Sulfonylurea receptor 1 (SUR1) is a subunit that regulates the activ-
ity of adenosine triphosphate (ATP)-sensitive potassium channels and
the ATP/Ca2+ nonselective cation channel [16]. SUR1 is upregulated
in neurons, astrocytes, and capillary endothelial cells following ischemic
stroke [17] and in neurons and endothelial cells in brain contusions
[18] and post–subarachnoid hemorrhage (SAH) inflammation [19].
The mechanism for glyburide activity in SAH appears to involve re-
arrangement of zona occludens-1 (ZO-1), a key protein of the endo-
thelial tight junction complex, and subsequent decreased vasogenic
edema, possibly by decreasing endothelial cytotoxic injury.
Glyburide is a potent SUR1 inhibitor [17] frequently used to treat
type II diabetes mellitus and has a minimal side effect profile consisting
primarily of hypoglycemia [20]. Glyburide has been reported to de-
crease stroke volume, post-stroke cerebral edema, and mortality fol-
lowing ischemic stroke [17], decrease microvascular fragmentation
and hemorrhage following traumatic brain contusion [18], and decrease
vasogenic edema SAH [19]. Because the blood-brain barrier is leaky in
cerebral metastases, we hypothesized that the expression of SUR1 is
increased and glyburide might decrease BTB permeability.
The primary objective of this study was to determine if SUR1 is
expressed in metastatic brain tumors in animal models and, if so, to
determine if inhibiting SUR1 with glyburide is effective in decreas-
ing BTB permeability as determined by dynamic contrast-enhanced
magnetic resonance imaging (DCE-MRI). DCE-MRI evaluates the
permeability of vessels using the measures transfer coefficient (K trans)
and extravascular extracellular space volume fraction (ve). In an intact
blood-brain barrier, K trans≈ 0 min−1 [21,22] and ve is unmeasurable
because ve can only be measured when contrast leaks from the vessels
to the extravascular extracellular space [23]. The secondary objectives
were to evaluate a putative relationship between SUR1 and ZO-1
and to determine if glyburide improves survival in brain tumor models.
Our results demonstrate that glyburide is a well-tolerated novel therapy
for decreasing the vasculature permeability of cerebral metastases.
Materials and Methods
Tumor Implantation
All procedures were approved by the Oregon Health & Science Uni-
versity (OHSU) Institutional Animal Care and Use Committee. LX1
human small cell lung carcinoma (SCLC) cells (obtained from Mason
Research Institute, Worcester, MA) were cultured in RPMI 1640
with 10% FBS and antibiotics. UW28 human malignant glioma cells
(courtesy of Dr Ali-Osman, Duke University, Durham, NC) and
A2058 human melanoma cells (ATCC, Manassas, VA) were grown
in Dulbecco’s modified Eagle’s mediumwith 10% FBS and antibiotics.
Nude rats (rnu/rnu) from the OHSU colony were sedated and under-
went stereotactic cell injection into right basal ganglia (BG; 3.2 mm
lateral to the bregma at a depth of 6.2 mm) as previously described [11].
Dynamic Contrast-Enhanced Magnetic Resonance Imaging
The initial (pretreatment) DCE-MRI was performed after intra-
cerebral cell implantation on day 7 for the LX1 group, days 9 and
10 for the A2058 group, and day 14 for the UW28 group. The second
(posttreatment) DCE-MRI was performed 48 hours later. Animals
were sedated and monitored during the MRI sessions in an (11.75 T)
MRI instrument (Bruker, Billerica, MA) as previously described [24].
Throughout the imaging session, warm air was continuously blown
through the bore to keep the animals’ body temperature between
35.5 and 37°C.
High-resolution rapid acquisition with refocused echo axial T2-
weighted images (repetition time/echo time = 4020 ms/12 ms,
rapid acquisition with refocused echo factor = 8, field of view = 3.2 ×
3.2 cm2, slice thickness = 1 mm, 25 slices, matrix = 256 × 256, one
average) was obtained and used to select the slice with the largest tumor
area to plan the DCE-MRI. Precontrast T1 value (T10) in tumor was
determined as previously described [24]. The DCE-MRI was per-
formed using a previously described inversion recovery sequence [24]
using 0.1 mM/kg gadodiamide. Precontrast and postcontrast high-
resolution T1-weighted images were acquired using a fast low-angle
shot sequence for tumor area measurements (repetition time/echo time =
160 ms/1.6 ms, field of view = 3.2 × 3.2 cm2, slice thickness = 1 mm,
25 slices, matrix = 256 × 256, four averages). Animals were stratified
into treatment groups (n = 6 per group) based on pretreatment high-
resolution coronal T2-weighted tumor size. Following the DCE-MRI
session, sedation was reversed using 1.25 mg of atipamezole hydro-
chloride (Zoetis, Florham Park, NJ).
Tumor Permeability and Size Calculation
All DCE-MRI data fitting and pharmacokinetic modeling was
performed using a nonlinear least squares method with an OHSU
in-house software package written in MATLAB (MathWorks, Inc,
Natick, MA). Animal-specific arterial input function was based on
the superior sagittal sinus. Amplitude of the arterial input function
was adjusted for each DCE-MRI experiment using the reference tissue
(temporalis muscle) method [24]. Tumor-specific, volume-averaged
T10 values measured from the inversion recovery (IR) sequence were
used in the analysis. Standard Toft’s two-compartment model [25] was
used for all cases to fit K trans and ve.
Each tumor region of interest was selected by a single author
(E.M.T.). Pixel-by-pixel DCE fast exchange limit maps were calculated.
Because the pixel-by-pixel maps demonstrated non-normally distrib-
uted K trans and ve in the tumor region of interest, the median values
of each were calculated using an OHSU software package written in
MATLAB (MathWorks, Inc).
The coronal slice with the largest tumor area as demonstrated
on high-resolution T2-weighted MRI was measured using ImageJ
[National Institutes of Health (NIH)]. Tumor area was also mea-
sured on the analogous slices in precontrast and postcontrast T1-
weighted MRI. Animals with tumors < 0.1 cm2 were excluded from
permeability analysis.
Medication Administration
Animals were administered vehicle, glyburide, or dexamethasone
after the pretreatment DCE-MRI. A 5-mg glyburide tablet was sus-
pended in 5 ml of DMSO. One milliliter of this solution was then
suspended in 100 ml of 0.9% NaCl (NS) creating a glyburide suspen-
sion of 1 mg/100 ml. The vehicle was prepared by suspending 1 ml of
DMSO in 100 ml of NS. The day following the pretreatment DCE-
MRI, animals were administered either 4.8 μg of glyburide or 480 μl of
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vehicle twice 8 hours apart through oral gavage or a single dose of
IV dexamethasone (0.35 mg) administered through the tail vein.
Following the posttreatment DCE-MRI, a subcutaneous pump was
implanted to deliver continuous treatment. A glyburide tablet (5 mg)
was dissolved in 1 ml of DMSO and then diluted in 11.5 ml of NS.
To prepare the vehicle, 1 ml of DMSO was added to 11.5 ml of NS.
Dexamethasone tablets (24 mg) were dissolved in 1 ml of DMSO
and then diluted in 3 ml of NS. These dilutions yielded a glyburide
delivery of 400 ng/hour and dexamethasone delivery of 3 μg/hour.
Following the posttreatment DCE-MRI, a small incision was made
between the scapulae, and a pump (0.5 μl/hour, Alzet model 2002)
filled with vehicle, glyburide, or dexamethasone was placed sub-
cutaneously. Approximately 7 hours following the first medication
administration and 24 hours following subcutaneous pump implanta-
tion, animals were sedated using isoflurane and a small lancet was used
to pierce a dorsal metatarsal vein. The serum glucose when evaluated
using an ACCU-CHEK glucometer. Animals were followed for sur-
vival and were examined at least every 2 days. Animals were sacrificed
if they demonstrated severe neurologic deficit or >20% weight loss.
Immunofluorescence
Animals were killed by intraperitoneal injection with 20 mg of
pentobarbital and intracardiac perfusion ofNS. Brains were flash frozen,
cryostat sectioned at 9 μm, and fixed in 4% formalin. Immuno-
histochemistry was performed using goat anti-SUR1 (Santa Cruz
Biotechnology, Dallas, TX) and rabbit anti–ZO-1 (Life Technologies,
Carlsbad, CA) at 1:200 dilutions. Slides were then incubated in species-
specific fluorescent antibodies (Life Technologies) for 60minutes, washed
with phosphate-buffered saline, and then incubated in 4′,6-diamidino-
2-phenylindole(Life Technologies) for 1 minute.
Six random high-powered fields (×200) from at least two histologic
sections of both the tumor and the contralateral BG were photographed
using standardized acquisition. Area of fluorescence was quantified
using ImageJ (NIH). Disruption of ZO-1 was quantified using ×400
images of six intratumoral vessels per animal. ImageJ (NIH) was used
to measure the total percentage of gap in the ZO-1 fluorescence for
each vessel. To assess the presence SUR1 and ZO-1 constitutive
expression in LX1 and A2058 cells in vitro, 1 × 105 of each cell
type was grown overnight in a six-well plate. The cells were prepared
for immunofluorescence using the aforementioned methods. All speci-
mens were visualized on Zeiss Axioplan microscope using a Zeiss
Axiocam camera.
Western Blot Analysis
Animals were killed by intraperitoneal injection with 20 mg of
pentobarbital and intracardiac perfusion of NS. The brains were
removed, and approximately 150-mg samples of tumor and normal
contralateral BG were excised, homogenized in radioimmunoprecipita-
tion assay buffer containing protease inhibitors, and frozen at −80°C.
Samples were then thawed, sonicated, and centrifuged at 14,000 rpm
for 20 minutes at 4°C. The supernatants were collected and pro-
teins were separated by electrophoresis, transferred, and blocked as
previously described [26]. Primary antibodies used were goat anti-
SUR1 (1:500; Santa Cruz Biotechnology), rabbit anti–ZO-1 (1:1000;
Life Technologies), or mouse anti-NeuN (1:1000; EMD Millipore,
Billerica, MA). The next day, membranes were washed three times in
tris-buffered saline with Tween20 (TBST) incubated for 1.5 hours with
appropriate HRP-conjugated secondary antibodies, and washed three
more times in TBST. The targeted antigens were visualized using
standard enhanced chemiluminescence methods (Amersham ECL)
and X-ray film. SUR-1 and ZO-1 bands were normalized to NeuN.
To semiquantify target protein expression, blot images of at least three
animals per treatment group for both metastatic models were analyzed
using Un-Scan-It (Silk Scientific, Orem, UT).
Statistical Analysis
All statistical analyses were performed using Prism 4.0 (GraphPad
Software, Inc, La Jolla, CA). Permeability (K trans and ve), SUR1
expression, and ZO-1 disruption were compared for each of the
three treatment groups using analysis of variance with Tukey post hoc
comparisons. Protein expression of tumoral versus contralateral BG was
made using a two-tailed non-paired Student’s t test. Association between
tumor permeability, size, change in permeability, and survival was made
using Pearson correlation coefficient (r), and survival was compared
using a chi-square log rank test.
Results
SUR1 Is Overexpressed in Cerebral Metastases
The constitutive expression of SUR1 in the rodent brain varies with
anatomic location with relatively little expression in the BG [27]. The
first step was to confirm that SUR1 expression was increased by cerebral
metastases and thus amenable to inhibition with glyburide. First, we
established that neither cell line constitutively expressed SUR1 in vitro.
LX1 and A2058 cells had no immunofluorescent activity for SUR1
compared to rodent brain specimens with known SUR1 expression
(P < .01). Next, we determined that SUR1 expression was significantly
increased (P < .05) in the tumor regions of both SCLC and melanoma
models compared to the contralateral BG where there was little con-
stitutive expression (Figure 1, A,–C). SUR1 was expressed in the peri-
cellular areas of tumor cells (Figure 1A) in glial and endothelial cells.
In both metastatic models, there was no difference in SUR1 expression
when the three treatment groups were compared using analysis of
variance (P > .05). Tumor region SUR1 overexpression was supported
by Western blot data (Figure 1, D and E).
Inhibition of SUR1 Decreases the BTB Permeability
of Cerebral Metastases
We sought to determine if inhibiting SUR1 with glyburide would
decrease BTB permeability and, if so, how this decrease in permeability
compared to the decrease in permeability conferred by the standard treat-
ment of tumor-related vasogenic edema, dexamethasone [9]. Vehicle
served as the negative control, dexamethasone served as the positive con-
trol, and glyburide served as the experiment. To eliminate selection bias,
we established that there was no difference in pretreatment (baseline)
T2-weighted or post-gadodiamide T1-weighted MRI tumor area,
K trans, or ve between the three treatment groups in either metastatic
tumor model (P > .05). Importantly, there was also no difference in
serum glucose measurements between the three groups and no animal
had a serum glucose less than 100 mg/dl (normal 82–187 mg/dl [28])
after treatment with either glyburide or dexamethasone.
As expected, permeability of BTB as determined by K trans of ani-
mals in the control group increased by approximately 100% in both
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Figure 1. SUR1 is overexpressed in cerebral metastases. Representative histologic sections of a control animal with implanted SCLC LX1
cells (A, ×200) demonstrate robust SUR1 expression (fluorescent green) in glial cells compared to the contralateral BG with minimal con-
stitutive expression. SUR1 expression is significantly higher in areas of cerebral SCLC (B) and melanoma (C) than contralateral BG
as assessed by immunofluorescent staining. Western blots (D and E) also demonstrate increased SUR1 expression in tumoral regions. Bars
are SEM. Scale bar, 20 μm. A.U., arbitrary units; Veh, vehicle; Gly, glyburide; Dex, dexamethasone, *P < .05.
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SCLC and melanoma models as the tumor size increased (Figure 2, A
and D). Following treatment, both glyburide and dexamethasone
significantly decreased BTB permeability as determined by K trans
compared to controls in animals with SCLC (P < .01; Figures 2, B and
C , and 3A). Glyburide significantly halted BTB permeability increase
compared to controls in animals with melanoma (P < .05; Figures 2E
and 3C ). Dexamethasone also limited BTB permeability increase
(Figures 2F and 3C) compared to controls in animals with melanoma,
but this difference was not statistically significant. Glyburide and dexa-
methasone did not significantly alter ve (Figure 3, B and D).
In a pilot study analyzing the effect of glyburide on a malignant
glioma model (UW28 cells), animals were treated with doses of
glyburide up to 9.8 μg twice daily. In contrast to both cerebral metas-
tasis models, inhibition of SUR1 failed to limit the increase in BTB
permeability associated with tumor growth. Treatment with neither
glyburide nor dexamethasone restricted increases in K trans (mean ±
SEM): 49.3 ± 22.2% in the vehicle group, 84.1 ± 38.3% in the
glyburide group, and 79.7 ± 52.0% in the dexamethasone group.
ve also increased in all groups (mean ± SEM): 136.9 ± 69.7% in the
vehicle group, 23.93 ± 49.3% in the glyburide group, and 118.1 ±
98.4% in the dexamethasone group. This arm of the study was termi-
nated due to treatment futility. Of note, no animal that received 9.8 μg
of glyburide twice daily had serum blood glucose levels < 100 mg/dl.
SUR1 and Dexamethasone Decrease Tumor-Induced
ZO-1 Gap Formation
Both hypoxia and inflammation, microenvironments found in
tumors [29], rearrange and create gaps in ZO-1 at the blood-brain
barrier [19,30]. Because inhibition of SUR1 has been linked to the
rearrangement of ZO-1 in inflammation [19], we sought to explore
the relationship of SUR1 and ZO-1 in metastatic tumors.
Animals in both metastatic models treated with glyburide or dexa-
methasone had significantly less ZO-1 gap distances compared to con-
trols (P < .01; Figure 4, A–C). In some cases, SUR1 was expressed in
the endothelial cells of vessels, co-localized with ZO-1 (Figure 4D).
Notably, the expression of ZO-1 was not decreased by the presence
of tumor when compared to contralateral BG (data not shown).
Decreased Tumor Vessel Permeability Does Not Correlate
with Survival
In both metastatic models in all three treatment groups, tumor area
increased in the 48 hours between the two DCE-MRI sessions (P >
Figure 2. Glyburide and dexamethasone decrease permeability in cystic and solid tumors regardless of size but do not inhibit tumor growth.
Representative coronalDCE and anatomicMR images froma single LX1SCLCanimal (A–C) in each treatment groupbefore treatment and 48 hours
later after treatment. Note the cystic nature of the SCLC tumors. Tumors in control animals (vehicle) demonstrate expected increased permeability
as the tumor becomes larger (A). Administration of glyburide results in a decrease in K trans and ve (B). Administration of dexamethasone results in a
decrease in K trans and ve (C). Representative coronal DCE and anatomicMR images from a single A2058melanoma animal (D–F) in each treatment
group before treatment and 48 hours later after treatment. Note the solid nature of the melanoma tumors and the large pretreatment size.
Tumors in control animals demonstrate significant increase in K trans, while ve minimally increases as the tumor becomes larger (C). In con-
trast, administration of glyburide results in stable K trans and ve values despite tumor growth (D). Administration of dexamethasone limits
increase of K trans, while the ve value in this animal increased (E). Veh, vehicle; Gly, glyburide; Dex, dexamethasone; Gd, gadodiamide.
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.05). As a result, we found no difference in median overall survival
between the three treatment groups in the SCLC model: vehicle
(16 days), glyburide (16 days), and dexamethasone (16.5 days) (P =
.735). There was a trend (P = .266) favoring increased survival in the
glyburide group in the melanoma model: vehicle (14 days), glyburide
(16.5 days), and dexamethasone (15 days). The rapid tumor growth
in these aggressive tumor models likely confounded any potential differ-
ence in survival conferred by decreasing vasogenic edema. As glyburide
is unlikely to have any direct cytotoxic effect on brain tumors, its clinical
benefit will likely result from edema reduction and subsequent quality
of life improvement, not survival prolongation.
Discussion
We demonstrated for the first time that SUR1 is overexpressed in
SCLC and melanoma cerebral metastases. We also established that
glyburide is at least as effective as dexamethasone at decreasing BTB
permeability in cerebral metastases. This finding was validated using
both negative (vehicle) and positive (dexamethasone) controls for
BTB permeability and held true in both cystic tumors (SCLC) and
solid tumors (melanoma). Further, we found that the decrease in per-
meability conferred by both glyburide and dexamethasone is at least in
part due to decreased tumor-induced ZO-1 gap formation.
The Role of SUR1 Inhibition in Malignant Brain Tumors
Although Simard and colleagues have explored the role of SUR1
in stroke [17], traumatic brain injury (TBI) [18], spinal cord injury
(SCI) [31], and SAH [19], SUR1 has not been reported as a mecha-
nism for the formation of vasogenic edema in cerebral metastases. In
a malignant glioma model, glyburide (5 μg/kg/min for 15 minutes) de-
creased the permeability conferred by monoxidil sulfate; however, no
decrease in permeability was found with glyburide administration alone
[32]. We found similar results in a pilot study using a UW28malignant
glioma model in which neither glyburide nor dexamethasone decreased
BTB permeability when given in amounts analogous to human doses.
This suggests that the mechanistic underpinning of tumor-induced
cerebral vasogenic edema differs in primarymalignant tumors andmeta-
static tumors and has important clinical implications. First, glyburide
may be an alternative to dexamethasone for the treatment of metastatic
cerebral tumors but may not be efficacious in malignant gliomas.
Second, higher doses of dexamethasone may be required to treat
Figure 3. Inhibition of SUR1 by glyburide decreases BTB permeability in SCLC and melanoma metastases. Animals with SCLC cerebral
metastases that received glyburide (mean K trans change ± standard error, −21.4 ± 14.2%) or dexamethasone (−14.2 ± 13.1%) had a
significant decrease in BTB permeability compared to controls (101.8 ± 36.6%) (A). Animals with melanoma cerebral metastases that re-
ceived glyburide had significantly less BTB permeability increase (3.2 ± 15.4%) compared to controls (117.1 ± 43.4%) (C). Dexamethasone
also lessened the permeability increase (63.1 ± 22.1%) compared to controls, but this did not reach statistical significance (C). Glyburide or
dexamethasone did not significantly affect ve in either metastatic model (B, D). Data are presented as the mean of six animals per group.
Bars represent SEM. Veh, vehicle; Gly, glyburide; Dex, dexamethasone; **P < .01, *P < .05.
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glioma-related edema compared tometastasis-related edema.Our group
previously demonstrated this concept in which 2 mg/kg dexamethasone
effectively decreased BTB in amalignant gliomamodel [12]. In contrast,
a dose of 0.34 mg/kg in this study effectively decreased BTB per-
meability in SCLC cerebral metastases but not in malignant glioma.
Future work will explore the intrinsic differences in BTB disruption
between primary malignant and metastatic brain tumors.
ZO-1 Preservation in Brain Tumors
SUR1 has been shown to be overexpressed in animal models of
inflammation due to SAH, which lead to ZO-1 rearrangement [19].
This presents a putative mechanism for the decrease of vasogenic edema
by the inhibition of SUR1 with glyburide. Although both glyburide
and dexamethasone administration correlated with a reduction in
tumor-induced ZO-1 gaps, pathways to this end are likely different.
We hypothesize that in cerebral metastases, glyburide blocks SUR1
in the endothelial cells, which likely prevents a cascade of cytotoxic
edema [31], disruption of the actin cytoskeleton and ZO-1 at the tight
junctions [33], and vasogenic edema. Glucocorticoids downregulate
VEGF [7,8], which prevents the VEGF-induced decrease in ZO-1
expression [34,35]. Given their different mechanisms, future studies
will determine if there is a synergistic relationship between glyburide
and dexamethasone in the preservation of ZO-1 integrity in the BTB.
Notably, in both models, we found no decrease in ZO-1 expression
in areas of tumor, only increases in ZO-1 gaps in the control groups.
Glyburide versus Dexamethasone
The dose of glyburide used in this study, the equivalent of 2.5 mg/
day in a 70-kg patient, is well tolerated in humans with mild hypo-
glycemia as the most common side effect [20]. In our study, no adverse
events were related to glyburide administration. In contrast, almost
50% of patients treated with glucocorticoids develop deficiencies in
Figure 4. Glyburide and dexamethasone decrease BTB permeability by preserving ZO-1 at endothelial cell tight junctions. Both glyburide
and dexamethasone administration result in significantly fewer and shorter gaps in ZO-1 compared to control animals that received vehicle
in both SCLC (A) and melanoma (B) models. Representative immunofluorescent sections (C, ×400) of melanoma cerebral metastases in
animals that received vehicle or glyburide. Note the continuous staining of ZO-1 in the glyburide-treated animal and the presence of mul-
tiple gaps (arrows) in ZO-1 staining in the vehicle-treated group. Representative histologic sections (D, ×400) of a control animal implanted
with A2058 melanoma cells with immunofluorescent SUR1 staining in the intratumoral endothelial cells (arrows) co-localizing with ZO-1
expression. Veh, vehicle; Gly, glyburide; Dex, dexamethasone; **P < .01, ***P < .001. Scale bar, 20 μm.
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glucose metabolism, and in nearly half of these patients, disturbances
persist despite reduction or even withdrawal of the drug [36]. Other
common adverse effects of dexamethasone include hyperglycemia,
peripheral edema, psychiatric disorders, immunosuppression, Cushing’s
syndrome, muscular weakness, femoral avascular necrosis, and pul-
monary embolus [10]. A 1 month supply of dexamethasone is approxi-
mately $22 [37]. Given the multitude of adverse effects with prolonged
dexamethasone use and the extraordinary expense of anti-VEGF anti-
bodies at approximately $9000 per month [15], glyburide, a generic
medication, may be an effective alternative to these agents for the treat-
ment of vasogenic edema at $30 monthly [38]. The modest price of
glyburide makes it amenable for widespread use in regions with limited
financial resources.
Assessing Brain Tumor Permeability Therapeutics
DCE-MRI, the method used to determine cerebral vasculature
permeability in this study, is arguably the most sophisticated way to
measure BTB permeability in humans. Preclinical studies that have
compared DCE-MRI versus quantitative autoradiography as a measure-
ment of vasculature permeability in tumor [39] and stroke models [32]
suggest that the two correlate extraordinarily well. However, DCE-
MRI has the distinct advantage of comparing permeability within a
single subject at multiple time points. We found that both glyburide
and dexamethasone decreased BTB permeability as measured by K trans,
whereas these two agents did not seem to effect ve. Since its inception,
K trans has been the gold standard for determining brain tumor per-
meably to which other methods are compared [40–42]. K trans has also
shown to be the permeability measure with the strongest correlation
of glioma [43] and breast cancer grade [44]. Future studies will be
conducted to determine the clinical relevance of ve.
Limitations
Despite a decrease in BTB permeability, animals that received
glyburide or dexamethasone did not survive significantly longer than
controls. As expected, neither agent inhibited tumor growth. The lack
of survival prolongation was likely due to the aggressive growth charac-
teristics of both LX1 and A2058 tumors with median survival ranging
from 14 to 16.5 days following tumor implantation. It is also possible
that treatment with glyburide or dexamethasone was commenced too
late to have a clinical effect. In humans with stroke, glyburide improved
functional outcome [45] (although that finding is controversial [46]),
but survival was not assessed. Future studies using less aggressive cell
types and neurofunctional assessment are needed to determine the
true clinical significance of decreased BTB permeability. It is certainly
possible that decreasing BTB permeability with glyburide may benefit
patients by reducing neurologic deficits associated with edema-related
mass effect without improving survival.
No animal in this study experienced hypoglycemia in doses up to
9.8 μg twice daily. However, rats eat almost continually while awake,
thus not replicating a typical human pattern of food consumption.
Hypoglycemia must therefore be closely monitored in the initial treat-
ment of patients with otherwise normal serum glucose.
In conclusion, SUR1 is overexpressed in SCLC and melanoma
cerebral metastases. Overexpression of SUR1 may be one of the key
mechanisms underlying cerebral metastatic tumor–related vasogenic
edema. The safe and inexpensive SUR1 inhibitor, glyburide, is at least
as effective as dexamethasone at decreasing BTB permeability in cere-
bral metastases. The decrease in permeability conferred by glyburide
and dexamethasone is likely due to the decreased formation of tumor-
induced gaps in the endothelial cell tight junction protein, ZO-1. This
is a key mechanistic finding to explain the effect of these medications
on BTB permeability.
The results of this work together with a long record of safe glyburide
use in humans support a clinical trial to assess the ability of glyburide
to decrease permeability as assessed by DCE-MRI and to investigate its
effects on cognitive and motor outcomes. Glyburide may be a viable
alternative to dexamethasone for the treatment of metastatic tumor–
related vasogenic edema. With minimal cost and side effects, glyburide
has the real potential to substantially improve quality of life in patients
with cerebral metastases.
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